Trial · NCT01020747
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
NCT01020747, Phase 1, Completed, Massachusetts General Hospital; results first posted 2012-12-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP). Trials, record NCT01020747. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01020747
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
- NCT number
- NCT01020747
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 20 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Recurrent Respiratory Papillomatosis
- Interventions
- Avastin® (bevacizumab), Saline
- First posted
- 2009-11-25
- Last updated
- 2012-12-20
- Results first posted
- 2012-12-04
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period. | 6 months | Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period. | 6 months | All subjects were analyzed. | total percentage change | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period. | Bevacizumab Treated Vocal Fold | 85.3 | Standard Deviation 68.6 | total percentage change | |
The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period. | Untreated Vocal Fold | 225.3 | Standard Deviation 191.1 | total percentage change |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group Avastin | 20 | |
| Overall Study | COMPLETED | Group Avastin | 19 | |
| Overall Study | NOT COMPLETED | Group Avastin | 1 |
Source ClinicalTrials.gov
Adverse events17
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Aguesia | Respiratory, thoracic and mediastinal disorders | Group Avastin | 1 | 20 | 1 |
| other | cold | Respiratory, thoracic and mediastinal disorders | Group Avastin | 1 | 20 | 1 |
| other | cough/URI | Respiratory, thoracic and mediastinal disorders | Group Avastin | 1 | 20 | 1 |
| other | disk herniation | Musculoskeletal and connective tissue disorders | Group Avastin | 1 | 20 | 1 |
| other | Diminished voice volume | Respiratory, thoracic and mediastinal disorders | Group Avastin | 1 | 20 | 1 |
| other | drainage and congestion | Respiratory, thoracic and mediastinal disorders | Group Avastin | 1 | 20 | 1 |
| other | dysphagia | Respiratory, thoracic and mediastinal disorders | Group Avastin | 2 | 20 | 2 |
| other | eye twitching | Eye disorders | Group Avastin | 1 | 20 | 1 |
| other | flu-like symptoms | Infections and infestations | Group Avastin | 1 | 20 | 1 |
| other | headache | General disorders | Group Avastin | 2 | 20 | 2 |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group Avastin | ||
| Total, other adverse events | Group Avastin | 20 | 20 |
| Total, serious adverse events | Group Avastin | 0 | 20 |
Source ClinicalTrials.gov
Papers22
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01020747
GET https://conductscience.org/api/trials/v1/NCT01020747/papers?page=2